Policy document
Expanding HPV Vaccination in the United States Through Policy Action: A Call for Legislative Support.
Grace K Kyei, Evans K Kyei ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001Human papillomavirus (HPV) vaccination rates among US children aged 9-17 are very low, with only 38.6% receiving at least one dose as of 2022. This low coverage results in approximately 36,000 preventable cancer cases annually and significant healthcare costs. The document calls for state legislators to implement policy measures including school-entry vaccination requirements, increased funding for equitable access, and provider education to improve vaccination rates. Implementation of these policies could prevent 90% of cervical cancers and save thousands of lives while reducing healthcare costs by an estimated $3.5 billion over a decade. Significant disparities exist between urban and rural areas.
Key points
- Only 38.6% of US children aged 9-17 have received one or more HPV vaccine doses as of 2022, with only 7.3% coverage among ages 9-10
- Approximately 36,000 preventable HPV-related cancer cases occur annually in the US, with an economic burden exceeding $1.7 billion
- Significant disparities exist with metropolitan areas having 39.4%-41.1% coverage compared to nonmetropolitan areas at 30.0%
- Policy recommendations include school-entry requirements, enhanced funding for equitable access, and provider education
- Full implementation could prevent 90% of cervical cancers and save approximately $3.5 billion in healthcare costs over a decade
Limitations
This is a policy brief advocating for action rather than an empirical study, so it does not present original research data on the effectiveness of specific policy interventions already implemented. The document projects potential outcomes of proposed policies but does not evaluate actual results from implemented programs.
Abstract
Human papillomavirus (HPV) vaccination remains significantly underutilized despite its proven efficacy in preventing cancer. As of 2022, only 38.6% of children ages 9 to 17 years have received one or more HPV vaccine doses, with particularly low coverage among younger children (7.3% for ages 9-10 years) who would benefit most from early vaccination. This results in approximately 36,000 preventable HPV-related cancer cases annually, with an economic burden exceeding $1.7 billion. Significant disparities exist between metropolitan (39.4%-41.1%) and nonmetropolitan areas (30.0%). This brief presents evidence-based policy recommendations for state legislators to increase HPV vaccination rates through school-entry requirements, enhanced funding for equitable access, and provider education targeting children and adolescents aged 9 to 17 years. Implementation of these measures could prevent 90% of cervical cancers and substantially reduce five other HPV-related cancers, saving thousands of lives annually while lowering healthcare costs by an estimated $3.5 billion over a decade. Immediate action is essential to protect the current generation from future cancer risk.